Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Total Equity
Idorsia Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Idorsia Ltd
SIX:IDIA
|
Total Equity
-CHf968.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
AC Immune SA
NASDAQ:ACIU
|
Total Equity
CHf130.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
||
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Equity
$1.9B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
||
Molecular Partners AG
SIX:MOLN
|
Total Equity
CHf155.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
||
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Equity
CHf16.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
||
Kuros Biosciences AG
SIX:KURN
|
Total Equity
CHf60.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Total Equity?
Total Equity
-968.7m
CHF
Based on the financial report for Dec 31, 2023, Idorsia Ltd's Total Equity amounts to -968.7m CHF.
What is Idorsia Ltd's Total Equity growth rate?
Total Equity CAGR 1Y
-47%
Over the last year, the Total Equity growth was -47%.